Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potential pathologic markers for prostate chemoprevention studies.

Wael A Sakr1, M Scott Lucia

  • 1Department of Pathology, School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI 48201, USA. waskr@med.wayne.edu

The Urologic Clinics of North America
|May 5, 2004
PubMed
Summary

Identifying prostate cancer biomarkers requires rigorous validation. Promising candidates must demonstrate technical feasibility and prove that altering their levels reduces cancer development rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.

European urology focus·2026
Same author

Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome.

Science translational medicine·2026
Same author

RETRACTED: Ahmad et al. Mechanisms and Therapeutic Implications of Cell Death Induction by Indole Compounds. <i>Cancers</i> 2011, <i>3</i>, 2955-2974.

Cancers·2025
Same author

Whole-Slide Telepathology Grading of Prostate Cancer in Biopsies Using International Society of Urological Pathology Criteria: Interobserver and Intraobserver Concordance and Implications for Active Surveillance.

The Journal of urology·2025
Same author

Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin.

AAPS open·2025
Same author

Emerging Strategies for Drug-Based Cancer Risk Reduction.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2025

Area of Science:

  • Oncology
  • Biomarker Discovery

Background:

  • Prostate cancer prevention research is rapidly advancing.
  • Histologic alterations like PIN are limited biomarkers.
  • New technologies and molecular targets show promise.

Purpose of the Study:

  • To review potential surrogate endpoint biomarkers for prostate cancer prevention trials.
  • To outline requirements for adopting new biomarkers.

Main Methods:

  • Review of emerging technologies (e.g., computer-assisted analysis).
  • Analysis of molecular candidates in cell-cycle regulation, angiogenesis, and chromosomal alterations.
  • Discussion of technical, interpretational, and validation needs.

Main Results:

Related Experiment Videos

  • A wide range of potential biomarkers exist beyond traditional histology.
  • Computer-assisted analysis and molecular markers are key areas.
  • Rigorous validation is essential before implementation.

    • Conclusions:

    • Potential biomarkers for prostate cancer prevention trials are expanding.
    • Technical, interpretational, and validation hurdles must be overcome.
    • Demonstrating a biomarker's ability to reduce cancer incidence is critical.